Waking up from the DREAM of preventing diabetes with drugs

British Medical Journal

Volumn 334, Issue 7599, 2007, Pages 882-884

  Montori, Victor ^a,c   Isley, William ^a   Guyatt, Gordon ^b  

^a Mayo Clinic   (United States)

^b MCMASTER UNIVERSITY   (Canada)

^c MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLIBENCLAMIDE; GLITAZONE DERIVATIVE; METFORMIN; PLACEBO; RAMIPRIL; ROSIGLITAZONE; ANTIDIABETIC AGENT;

ARTICLE; BONE DENSITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; COST BENEFIT ANALYSIS; DIABETES MELLITUS; DRUG FATALITY; DRUG MARKETING; DRUG MEGADOSE; HIGH RISK POPULATION; HUMAN; IMPAIRED GLUCOSE TOLERANCE; LIFESTYLE MODIFICATION; MEDICAL DECISION MAKING; MORBIDITY; MORTALITY; OSTEOLYSIS; OUTCOME ASSESSMENT; PHYSICAL ACTIVITY; PREVALENCE; PRIORITY JOURNAL; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL; RETINA MACULA EDEMA; RISK REDUCTION; SIDE EFFECT; TREATMENT DURATION; WEIGHT REDUCTION; REVIEW; TREATMENT OUTCOME;

DIABETES MELLITUS; HUMANS; HYPOGLYCEMIC AGENTS; TREATMENT OUTCOME; WEIGHT LOSS;

EID: 34247869069     PISSN: 09598146     EISSN: None     Source Type: Journal    
DOI: 10.1136/bmj.39169.447488.94     Document Type: Article

References (23)

1. International Diabetes Federation. Diabetes atlas. 2005. www.eatlas.idf.org.
2. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004;27:1047-53.
3. Roglic G, Unwin N, Bennett PH, Mathers C, Tuomilehto J, Nag S, et al. The burden of mortality attributable to diabetes: realistic estimates for the year 2000. Diabetes Care 2005;28:2130-5.
4. DREAM (Diabetes Reduction Assessment with Ramipril and Rosiglitazone Medication) Trial Investigators. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet 2006;368:1096-105.
5. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346:393-403.
6. Pan XR, Li GW, Hu YH, Wang JX, Yang WY, An ZX, et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and diabetes study. Diabetes Care 1997;20:537-44.
7. Tuomilehto J, Lindstrom J, Eriksson JG, Valle TT, Hamalainen H, Ilanne-Parikka P, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001;344:1343-50.
8. Heath I. Who needs health care - the well or the sick? BMJ 2005;330:954-6.
9. Moynihan R, Heath I, Henry D. Selling sickness: the pharmaceutical industry and disease mongering. BMJ 2002;324:886-91.
10. Padwal R, Majumdar SR, Johnson JA, Varney J, McAlister FA. A systematic review of drug therapy to delay or prevent type 2 diabetes. Diabetes Care 2005;28:736-44.
11. Buchanan TA, Xiang AH, Peters RK, Kjos SL, Marroquin A, Goico J, et al. Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk hispanic women. Diabetes 2002;51:2796-803.
12. Knowler WC, Hamman RF, Edelstein SL, Hamman RF, Lachin JM, Walker EA, et al. Prevention of type 2 diabetes with troglitazone in the diabetes prevention program. Diabetes 2005;54:1150-6.
13. McCall KL, Craddock D, Edwards K. Effect of angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor blockers on the rate of new-onset diabetes mellitus: a review and pooled analysis. Pharmacotherapy 2006;26:1297-306.
14. Bosch J, Yusuf S, Gerstein HC, Pogue J, Sheridan P, Dagenais G, et al. Effect of ramipril on the incidence of diabetes. N Engl J Med 2006;355:1551-62.
15. Montori VM, Jaeschke R, Schunemann HJ, Bhandari M, Brozek JL, Devereaux PJ, et al. Users' guide to detecting misleading claims in clinical research reports. BMJ 2004;329:1093-6.
16. Ferreira-González I, Permanyer-Miralda G, Domingo-Salvany A, Busse JW, Heels-Ansdell D, Montori VM, et al. Problems with use of composite end points in cardiovascular trials: systematic review of randomised controlled trials. BMJ 2007;334:786-8.
17. Montori VM, Permanyer-Miralda G, Ferreira-Gonzalez I, Busse JW, Pacheco-Huergo V, Bryant D, et al. Validity of composite end points in clinical trials. BMJ 2005;330:594-6.
18. Schwartz AV, Sellmeyer DE, Vittinghoff E, Palermo L, Lecka-Czernik B, Feingold KR, et al. Thiazolidinedione use and bone loss in older diabetic adults. J Clin Endocrinol Metab 2006;91:3349-54.
19. Tuomilehto J, Wareham N. Glucose lowering and diabetes prevention: are they the same? Lancet 2006;368:1218-9.
20. Thoolen BJ, de Ridder DT, Bensing JM, Gorter KJ, Rutten GE. Psychological outcomes of patients with screen-detected type 2 diabetes: the influence of time since diagnosis and treatment intensity. Diabetes Care 2006;29:2257-62.
21. Kendall C, Wooltorton E. Rosiglitazone (Avandia) and macular edema. CMAJ 2006;174:623.
22. Kahn SE, Haffner SM, Heise MA, Herman WH, Holman RR, Jones NP, et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006;355:2427-43.
23. Dormandy JA, Charbonnel B, Eckland DJ, Erdmann E, Massi-Benedetti M, Moules IK, et al. zSecondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005;366:1279-89.